ABUS vs ECL
Arbutus Biopharma Corp (ABUS) versus Ecolab Inc (ECL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Not investment advice. Open the ABUS and ECL stock pages for the full models.
Not investment advice.